Lacouture ME - Search Results

1

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Fischer A, Wu S, Ho AL, Lacouture ME. Fischer A, et al. Among authors: lacouture me. Invest New Drugs. 2013 Jun;31(3):787-97. doi: 10.1007/s10637-013-9927-x. Epub 2013 Jan 24. Invest New Drugs. 2013. PMID: 23345001 Review.

2

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.

Chu D, Lacouture ME, Fillos T, Wu S. Chu D, et al. Among authors: lacouture me. Acta Oncol. 2008;47(2):176-86. doi: 10.1080/02841860701765675. Acta Oncol. 2008. PMID: 18210295 Review.

3

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Rosenbaum SE, et al. Among authors: lacouture me. Support Care Cancer. 2008 Jun;16(6):557-66. doi: 10.1007/s00520-008-0409-1. Epub 2008 Feb 15. Support Care Cancer. 2008. PMID: 18274784 Review.

4

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Lacouture ME, et al. Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. Oncologist. 2008. PMID: 18779536 Free article. Review.

5

Blackberry-induced hand-foot skin reaction to sunitinib.

Boone SL, Jameson G, Von Hoff D, Lacouture ME. Boone SL, et al. Among authors: lacouture me. Invest New Drugs. 2009 Aug;27(4):389-90. doi: 10.1007/s10637-008-9196-2. Epub 2008 Nov 8. Invest New Drugs. 2009. PMID: 18998055

6

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.

Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Tejwani A, et al. Among authors: lacouture me. Cancer. 2009 Mar 15;115(6):1286-99. doi: 10.1002/cncr.24120. Cancer. 2009. PMID: 19170238 Free article.

7

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.

Chu D, Lacouture ME, Weiner E, Wu S. Chu D, et al. Among authors: lacouture me. Clin Genitourin Cancer. 2009 Jan;7(1):11-9. doi: 10.3816/CGC.2009.n.002. Clin Genitourin Cancer. 2009. PMID: 19213662

8

Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.

Su X, Lacouture ME, Jia Y, Wu S. Su X, et al. Among authors: lacouture me. Oncology. 2009;77(2):124-33. doi: 10.1159/000229752. Epub 2009 Jul 22. Oncology. 2009. PMID: 19622903 Review.

9

Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.

Jia Y, Lacouture ME, Su X, Wu S. Jia Y, et al. Among authors: lacouture me. J Support Oncol. 2009 Nov-Dec;7(6):211-7. J Support Oncol. 2009. PMID: 20380328

10

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Balagula Y, et al. Among authors: lacouture me. Invest New Drugs. 2011 Oct;29(5):1114-21. doi: 10.1007/s10637-010-9567-3. Epub 2010 Oct 27. Invest New Drugs. 2011. PMID: 20978926 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters